tbuckley/cabot-search huggingface dataset:
Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER
Authors: F. Duffaud, J.-Y. Blay, A. Italiano, E. Bompas, M. Rios, N. Penel, O. Mir, S. Piperno-Neumann, C.M. Chevreau, C. Delcambre, F. Bertucci, P. Boudou Rouquette, H. Vegas, C. Perrin, A. Thyss, C. Schiffler, L. Monard, C. Bouvier, V. Vidal, S. Chabaud
Journal: Annals of Oncology (2019)
Utilization pattern of bone targeting agents in patients with solid tumour in Taiwan, Hong Kong and Korea
Authors: S.J.J. Lai, P.C.M. Au, Y.H. Baek, C.L. Cheung, S.N. Gao, Y H Kao Yang, N. Kleinman, J.H. Kim, J. Lange, T.C. Liao, T.C. Lin, K.K. Man, J.Y. Shin, C.W. Sing, I.C.K. Wong, E.C.C. Lai
Journal: Annals of Oncology (2019)
High-throughput DNA sequencing defines spatiotemporal shifts in airborne grass pollen communities at species level
Authors: G. W. Griffith, C. Potter, N. De Vere, M. Hegarty, G. L. Brennan, C. A. Skjoth, N. J. Osborne, B. W. Wheeler, F. M. Rowney, A. Barber, Y. Clewlow, R. N. Mcinnes, H. M. Hanlon, B. Adams-Groom, A. Kurganskiy, G. M. Petch, L. Jones, C. R. Ford, C. Armitage, S. Creer
Journal: Allergy (2019)
Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents: A meta-analysis of randomized controlled trials
Authors: R Coutinho Mariano, L.M. Gomes, C. Oliveira, A.C. Galdino, J.A.P. Araújo, D. Vargas, F.C. Maluf, G.A. De Velasco Oria de Rueda, F.A.B. Schutz
Journal: Annals of Oncology (2019)
NF-κB Blockade Induces Apoptosis and Decreases Costimulatory Molecules and IL-12 Secretion of Dendritic Cells, Altering DC Maturation: Role in Induction of Tolerance after Transplantation.
Authors: Luis I. Sanchez Abarca, Jose A. Perez-Simon, Belen Blanco, Norma Gutierrez, Juan Mateos, Belen Vidriales, Natalia Lopez-Holgado, Mercedes Alberca, Eva Villaron, D. Schenkein, Consuelo Canizo, Jesus F. San Miguel
Journal: Blood (2005)
Primary Prevention of Cardiovascular Disease
Authors: Atul Jain, Andrew M. Davis
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)
Authors: N. Agarwal, K. McQuarrie, A. Bjartell, S. Chowdhury, A J P D S Gomes, B.H. Chung, M. Özgüroğlu, Á Juárez Soto, A. Merseburger, H. Uemura, D. Ye, R. Given, B. Miladinovic, L. Dearden, K. Deprince, V. Naini, A. Lopez-Gitlitz, K.N. Chi
Journal: Annals of Oncology (2019)
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies
Authors: F. Marmorino, D. Rossini, S. Lonardi, R. Moretto, G. Zucchelli, G. Aprile, E. Dell’Aquila, M. Ratti, F. Bergamo, G. Masi, F. Urbano, M. Ronzoni, M. Libertini, B. Borelli, G. Randon, A. Buonadonna, G. Allegrini, N. Pella, V. Ricci, A. Boccaccino, T.P. Latiano, S. Cordio, A. Passardi, E. Tamburini, L. Boni, A. Falcone, C. Cremolini
Journal: Annals of Oncology (2019)
Prognostic role of CD73 in metastatic non small cell lung cancer according to the presence of driver alterations
Authors: G. Galli, R. Ferrara, F. Pagani, A. De Toma, G. Lo Russo, D. Signorelli, A. Prelaj, N. Zilembo, M. Ganzinelli, S. Brich, A. Fabbri, S. Sangaletti, G. Pruneri, M.P. Colombo, F.G.M. de Braud, M.C. Garassino, C. Proto
Journal: Annals of Oncology (2019)
Analysis of tumour samples from SOLO1: Frequency of BRCA specific loss of heterozygosity (LOH) and progression-free survival (PFS) according to homologous recombination repair deficiency (HRD)-LOH score
Authors: C. Gourley, J.S. Brown, Z. Lai, P. Lao-Sirieix, C.E. Elks, H. McGarvey, T. French, T. Milenkova, R. Bloomfield, P. Rowe, D. Hodgson, J.C. Barrett, K. Moore, P. DiSilvestro, E.A. Harrington
Journal: Annals of Oncology (2019)
Increased Circulating Nucleosomes and Neutrophil Activation As a Measure of the Formation of Neutrophil Extracellular Traps (NETs) During Sickle Cell Painful Crisis
Authors: Marein Schimmel, Erfan Nur, Sacha Zeerleder, Gerard J van Mierlo, Shabnam Solati, Dees P Brandjes, Hans-Martin Otten, John-John Schnog, Bart J Biemond
Journal: Blood (2012)
Cancer screening: Source of information and level of trust.
Authors: Jean F. Morere, Jérôme Viguier, Yvan Coscas, Xavier B. Pivot, Jean-Yves Blay, Francois Eisinger, Christine Lhomel
Journal: Journal of Clinical Oncology (2012)

1567 Background: Providing public information is critical for cancer control. EDIFICE surveys were conducted to provide a better understanding of the participation of the French population in cancer screening programs (colorectal, breast) or individual cancer screening (prostate). To evaluate sources of information in the general population and their level of trust, specific questions were addressed in the EDIFICE 3 survey. Methods: This third nationwide observational study, EDIFICE 3, was conducted by phone interviews among a representative sample of 1603 subjects aged between 40 and 75 years old, using the quota method. Questions on the source of information were: Concerning cancer screening, what are all your means of information? What level of trust (quoted from 1 to 10) do you have on the following media of information; your own general practitioner, physicians in general, patient associations, national health insurance system, health authorities, your close circle, radio and television, lay press, internet. Results: In the overall population, the most frequently quoted means of information for cancer screening were: radio and television (61%), general practitioners (52%), lay press (33%), institutional letters (19%) and internet (18%). People under 50 years old named significantly more often radio and television (66% vs 58%) and internet (24% vs 15%), while older people above 50 years old (target population for screening programs) more frequently named institutional letters (26% vs 7%). In a trust scale from 0 to 10, the best level of trust was achieved by general practitioners (8.2), patient associations (6.8), national health insurance system (6.6) and health authorities (6.2). In contrast, radio and television (5.7), lay press (5.2) and internet (4.6) were mistrusted. Overall, women and younger subjects were more trustful. Conclusions: Radio and television are the most frequently quoted source of information but paradoxically they are not highly trusted. The general practitioner appears to be the best option (trusted and used) for providing cancer screening information. As institutional letters were frequently quoted and highly trusted, they might be useful for informing the population even before the age of recommended screening.
Abstract 14386: Can 2-Dimensional Echocardiography Provide Accurate Assessments of Right Ventricular Volume and Systolic Function in Patients With Pulmonary Hypertension?
Authors: Laila A Payvandi, Manjula V Burri, Dipti Gupta, Denice S Daly, Melissa K Davis, Richard E Kerber, Robert M Weiss
Journal: Circulation (2011)

Background: Right ventricular (RV) morphology and systolic function are major determinants of survival in patients with pulmonary arterial hypertension (PAH). However, quantitation is problematic w...
Prognostic value of metabolic response assessed by 18FDG-PET after induction chemotherapy and after chemoradiotherapy (CRT) in localized esophageal squamous cell carcinoma (ESCC) patients (pts) receiving definite CRT (dCRT)
Authors: Y. Bang, H. Jeong, H.-S. Im, S.R. Park
Journal: Annals of Oncology (2019)
Whole transcriptomics analyses of mimicking circulating tumor cells (CTCs) by single-cell RNA sequencing (scRNAseq)
Authors: J. Garcia, F. Monjaret, F. Geiguer, J.-P. Aurel, A. Puisieux, A.P. Morel, C. Bardel, G. Vilchez, M. Brigitte, S. Couraud, A. Vigneron, G. Tourniaire, L.F. Payen-Gay
Journal: Annals of Oncology (2019)
Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women
Authors: Amita Gupta, Grace Montepiedra, Lisa Aaron, Gerhard Theron, Katie McCarthy, Sarah Bradford, Tsungai Chipato, Tichaona Vhembo, Lynda Stranix-Chibanda, Carolyne Onyango-Makumbi, Gaerolwe R. Masheto, Avy Violari, Blandina T. Mmbaga, Linda Aurpibul, Ramesh Bhosale, Vidya Mave, Vanessa Rouzier, Anneke Hesseling, Katherine Shin, Bonnie Zimmer, Diane Costello, Timothy R. Sterling, Nahida Chakhtoura, Patrick Jean-Philippe, Adriana Weinberg
Journal: New England Journal of Medicine (2019)

The safety, efficacy, and appropriate timing of isoniazid therapy to prevent tuberculosis in pregnant women with human immunodeficiency virus (HIV) infection who are receiving antiretroviral therapy are unknown.
Systemic gut microbial metabolites limit the anti-tumour effect of CTLA-4 blockade in hosts with cancer
Authors: C. Coutzac, J.-M. Jouniaux, A. Paci, V. Asvatourian, P. Saulnier, L. Lacroix, F. Carbonnel, P.A. Ascierto, C. Robert, N. Chaput
Journal: Annals of Oncology (2019)
Cryopreserved G-CSF Mobilized Donor Lymphocyte Infusion (DLI) without Withdrawal of Immunosuppression Is Safe and Highly Effective for Treating Isolated Poor Donor T-cell Chimerism Following Reduced Intensity Allogeneic Transplantation (RICT).
Authors: Asad Bashey, Karen L Manion, Pauline Smith, Joan Mccollum, H. Kent Holland, Lawrence E. Morris, Scott R. Solomon
Journal: Blood (2009)
First-in-human, first-in-class phase I study of MTL-CEBPA, a RNA oligonucleotide targeting the myeloid cell master regulator C/EBP-α, in patients with advanced hepatocellular cancer (HCC)
Authors: D. Sarker, R. Plummer, B. Basu, T. Meyer, Y.-T. MA, J. Evans, D.H. Palmer, K.-W. Huang, C.E. Chee, D. Spalding, M. Sodergren, N. Habib
Journal: Annals of Oncology (2019)
Lenvatinib (Len) alone or in combination with everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Authors: A.J. Wiele, J. Ross, J. Chahoud, Z. Lim, L. Xiao, M.T. Campbell, A.Y. Shah, A. Zurita Saavedra, E. Jonasch, N.M. Tannir
Journal: Annals of Oncology (2019)
Rational Design of Rapidly Separating Dissolving Microneedles for Precise Drug Delivery by Balancing the Mechanical Performance and Disintegration Rate
Authors: Ailin Hou, Guilan Quan, Beibei Yang, Chao Lu, Minglong Chen, Dan Yang, Lili Wang, Hu Liu, Xin Pan, Chuanbin Wu
Journal: Advanced Healthcare Materials (2019)

Abstract The precise delivery of traditional dissolving microneedles (TDMNs) is often limited by the incomplete insertion due to the skin deformation, and the topical irritation is inevitable after long application, which ultimately results in compromised therapeutic efficacy. The aim of this study is to develop a rapidly separating dissolving microneedles (RSDMNs) system to achieve precise drug delivery. Therapeutic molecules are concentrated in the needle tip, while the blank separating part allows it to counteract skin indentation and rapidly separate from the base part. For rational design of an ideal separating part, and the molecular interactions between polymer and sugar are explored to make a good balance between mechanical performance and disintegration rate. The optimal RSDMNs can rapidly disintegrate in the mimic skin within 30 s, and the generated micropores in the skin reseal quickly. The ex vivo drug permeation of RSDMNs is significantly higher than that of TDMNs due to the complete needle imbed aided by the separating part. Furthermore, RSDMNs exhibit excellent in vivo anti‐inflammation effect by remarkably down regulating the expression of TNF‐α, IL‐1β, and IL‐6. In conclusion, the RSDMNs can reach precise drug delivery in a short time, which are more reliable for the self‐administration strategy in the future.
ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer
Authors: Yun-Han Huang, Jing Hu, Fei Chen, Nicolas Lecomte, Harihar Basnet, Charles J. David, Matthew D. Witkin, Peter J. Allen, Steven D. Leach, Travis J. Hollmann, Christine A. Iacobuzio-Donahue, Joan Massagué
Journal: Cancer Discovery (2019)

Abstract TGFβ is an important tumor suppressor in pancreatic ductal adenocarcinoma (PDA), yet inactivation of TGFβ pathway components occurs in only half of PDA cases. TGFβ cooperates with oncogenic RAS signaling to trigger epithelial-to-mesenchymal transition (EMT) in premalignant pancreatic epithelial progenitors, which is coupled to apoptosis owing to an imbalance of SOX4 and KLF5 transcription factors. We report that PDAs that develop with the TGFβ pathway intact avert this apoptotic effect via ID1. ID1 family members are expressed in PDA progenitor cells and encode components of a set of core transcriptional regulators shared by PDAs. PDA progression selects against TGFβ-mediated repression of ID1. The sustained expression of ID1 uncouples EMT from apoptosis in PDA progenitors. AKT signaling and mechanisms linked to low-frequency genetic events converge on ID1 to preserve its expression in PDA. Our results identify ID1 as a crucial node and potential therapeutic target in PDA. Significance: Half of PDAs escape TGFβ-induced tumor suppression without inactivating the TGFβ pathway. We report that ID1 expression is selected for in PDAs and that ID1 uncouples TGFβ-induced EMT from apoptosis. ID1 thus emerges as a crucial regulatory node and a target of interest in PDA. This article is highlighted in the In This Issue feature, p. 1
A user-friendly nomogram to predict relapse-free survival (RFS) in western patients with resected gastric cancer (GC)
Authors: M. Salati, S. Pipitone, M. Rimini, F. Gelsomino, A. Casadei-Gardini, K. Andrikou, F.M. Schipilliti, G. Cortesi, L. Cassanelli, E. Caffari, F. Serra, A. Ricciardolo, N. De Ruvo, R. Gelmini, S. Cascinu, A. Spallanzani
Journal: Annals of Oncology (2019)
HORAS5 promotes cabazitaxel resistance in castration resistant prostate cancer via a BCL2A1-dependent survival mechanism
Authors: P. Pucci, E. Venalainen, I. Alborelli, L. Quagliata, R. Mather, S. Rigas, I. Romero, Y. Wang, F. Crea
Journal: Annals of Oncology (2019)
Macmillan’s guidance on prehabilitation
Authors: June Davis
Journal: BMJ (2019)

Giles and Cummins discuss our report on prehabilitation for people with cancer.12 We recognise the barriers to successful implementation that they mention and are working with NHS leaders to tackle them.

We agree that the evidence base for prehabilitation must be strengthened. Our report recommends building on evidence gaps and, critically, getting a further understanding of the patient prehabilitation …
A phase II biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need
Authors: K. Yonemori, T. Shimizu, T. Koyama, N. Matsui, H.S. Okuma, E. Noguchi, K. Sudo, A. Hirakawa, T. Sukigara, S. Fujitani, K. Nakamura, K. Tamura, N. Yamamoto, Y. Fujiwara
Journal: Annals of Oncology (2019)
FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer
Authors: Alain Mangé, Etienne Coyaud, Caroline Desmetz, Estelle Laurent, Benoit Béganton, Peter Coopman, Brian Raught, Jérôme Solassol
Journal: Theranostics (2019)

et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Non-BRCA1/2 hereditary breast and ovarian cancer: Findings from a multidisciplinary program
Authors: A. Monteiro, P. Machado, A.I. Clara, A. Opinião, A. Luis, I. Miguel, P. Louro, S. Santos, S. Fragoso, P. Rodrigues, F. Rodrigues, I. Coelho, J. Parreira, F. Vaz
Journal: Annals of Oncology (2019)
EXTERNAL VALIDATION OF THE ORBIT BLEEDING AND THE HAS-BLED SCORE IN ATRIAL FIBRILLATION PATIENTS USING DIRECT ORAL ANTICOAGULANTS: SUBANALYSIS OF THE DIRECT REGISTRY
Authors: Naoki Mori, Yohei Sotomi, Akio Hirata, Atsushi Hirayama, Yoshiharu Higuchi
Journal: Journal of the American College of Cardiology (2019)
Urine cell-free and extracellular vesicle cargo miRNAs as biomarkers for prostate cancer diagnosis
Authors: I.A. Zaporozhchenko, O.E. Bryzgunova, M.Y. Konoshenko, E.A. Lekchnov, E.V. Amelina, O.A. Pashkovskaya, S.V. Yarmoschuk, A.A. Zheravin, E.Y. Rykova, P.P. Laktionov
Journal: Annals of Oncology (2019)
A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumours
Authors: A.C. Tan, A.O.L. Seet, S.P. Choo, D.W.M. Tai, Y.C.J. Lam, W.T. Teng, C. Lim, K.H. Lim, M.C.H. Ng
Journal: Annals of Oncology (2019)
A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours
Authors: A.M. Schram, A. Drilon, T Macarulla Mercade, E.M. O’Reilly, J.A. Rodon, B.M. Wolpin, S-H I Ou, D.-W. Kim, J C-H Yang, Y.C.J. Lam, A. Varga, A.J. de Langen, P.O. Witteveen, V. Boni, G. Cerea, M. Duruisseaux, S.V. Liu, E. Wasserman, D.M. Hyman, J. Tabernero
Journal: Annals of Oncology (2019)
Inhibition of Rspo-Wnt pathway facilitates checkpoint blockade therapy by anti-RSPO3 antibody (DBPR117)
Authors: J T-A Hsu, H.-C. Hung, C.-T. Chen, W.-C. Yen, T.-Y. Chang, P.-K. Chao, H. Chin-Ting, K.-J. Yen, Y.-R. Tsai, C.-Y. Chang, M.-Y. Fang, Y.-L. Lai, J.C. Shih
Journal: Annals of Oncology (2019)
Association of Clinical Frailty Scores With Hospital Readmission for Falls After Index Admission for Trauma-Related Injury
Authors: Victor H. Hatcher, Colette Galet, Michele Lilienthal, Dionne A. Skeete, Kathleen S. Romanowski
Journal: JAMA Network Open (2019)

Falls have been associated with morbidity and mortality in elderly patients. Assessment of frailty at hospital admission may help health care professionals evaluate fall risk in patients with trauma-related injury.To determine whether frailty assessed using the Canadian Study of Health and Aging Clinical Frailty Scale is associated with readmission for falls after index admission for trauma-related injury in patients aged 50 years and older.This retrospective cohort study reviewed the medical records of 804 patients aged 50 years and older with trauma-related injury who were admitted to the University of Iowa Hospitals and Clinics between July 1, 2010, and June 30, 2015. Records were reviewed from May 30 to August 1, 2017, and patient demographics, admission data, injury severity scores, history of falls, and postindex readmission data for ground-level falls were recorded. Frailty scores were calculated using the Canadian Study of Health and Aging Clinical Frailty Scale. Patients with a score of 5 or higher were classified as frail.Frailty assessed using the Canadian Study of Health and Aging Clinical Frailty Scale and readmission for falls after index admission for trauma-related injury.A total of 804 patients with trauma-related injury were included in the study. The mean (SD) age was 70 (13.4) years; 744 patients (93.4%) were white, and 380 (47.3%) were men. Among the total population, the mortality rate was 3.7%; 255 patients (31.7%) were classified as frail and 549 (68.3%) as nonfrail. The mean (SD) injury severity score was 9.8 (7.9), and the score was similar between frail and nonfrail patients. Of 255 frail patients, 179 (70.2%) were women, and frail patients were significantly older than nonfrail patients (mean [SD], 79.2 [12.1] years vs 66.2 [11.9] years, respectively; P < .001). The percentages of frail patients presenting to the hospital with a history of falls and readmitted for falls after index admission were higher than those of nonfrail patients (63 [24.8%] vs 53 [9.6%] and 55 [21.6%] vs 58 [10.6%], respectively; both P < .001). Frailty was associated with discharge to the home with health care (odds ratio [OR], 4.82; 95% CI, 2.10-11.01; P < .001), to a skilled nursing facility (OR, 5.47; 95% CI, 3.40-8.80; P < .001), and to a hospice care facility (OR, 8.47; 95% CI, 2.09-34.42; P = .003) compared with discharge to the home with self-care. Frailty was also associated with readmission for falls after index admission (OR, 2.26; 95% CI, 1.39-3.66; P = .001) and the number of falls within 1 year after index admission (OR, 1.32; 95% CI, 1.04-1.67; P = .02) compared with nonfrailty. The frailty analysis was controlled for age, body mass index, sex, and falls at index admission.Measurement of frailty at hospital admission may be an effective tool to assess fall risk and discharge disposition among patients with trauma-related injury aged 50 years and older.
Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study
Authors: A. Casadei-Gardini, G. Marisi, V. Dadduzio, L. Faloppi, L. Ielasi, C. Vivaldi, M.D. Rizzato, L. Fornaro, S. Lonardi, L. Gramantieri, I. Pecora, N. Silvestris, F. Fornari, G. Orsi, G. Rovesti, D. Santini, V. Zagonel, S. Cascinu, M. Scartozzi
Journal: Annals of Oncology (2019)
A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumours
Authors: J. Pérez-Peña, J.T. Fekete, R. Páez, J.A. García-Sáenz, V. García-Barberán, P. Pérez-Segura, A. Pandiella, B. Gyorffy, A. Ocaña, A. Manzano
Journal: Annals of Oncology (2019)
Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses
Authors: A. Ravaud, J.-F. Martini, K. Ching, M. Staehler, A. Magheli, B. Escudier, X.J. Mu, O. Valota, X. Lin, R.J. Motzer
Journal: Annals of Oncology (2019)
Correction: LOXL2-Mediated Matrix Remodeling in Metastasis and Mammary Gland Involution
Authors: Holly E. Barker, Joan Chang, Thomas R. Cox, Georgina Lang, Demelza Bird, Monica Nicolau, Holly R. Evans, Alison Gartland, Janine T. Erler
Journal: Cancer Research (2019)

In the original version of [this article][1] ([1][2]), the same β-actin control was duplicated in Fig. 5B and Supplementary Fig. S6A. This duplication was intentional, as the data were derived from the same Western blot experiment. The legend of Fig. 5B has been corrected to state this in the